Moderna's mRNA cancer vaccine trial success leads to significant stock surge

Youtube

·

Original Report

↗ Youtube

Moderna's stock jumped over 140% following successful late-stage trial results for its mRNA cancer vaccine, marking a positive market event that contrasts with other market movements driven by debt and efforts to prop up bonds. Moderna is characterized as an 'accidental beneficiary from COVID' alongside Zoom and Peloton.